Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Michael Burkes Brophy net worth and biography

Michael Brophy Biography and Net Worth

CFO of Natera
Mike Brophy has served as our Chief Financial Officer since February 2017. Previously, he served as our Senior Vice President, Finance and Investor Relations since September 2016, and prior to that, as our Vice President, Corporate Development and Investor Relations since September 2015. Prior to joining Natera, Mr. Brophy served as an executive director from January 2014 to September 2015, and as a vice president prior to that, in the investment banking division at Morgan Stanley where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds an M.B.A. from the University of California, Los Angeles and a Bachelor of Science in Economics from the United States Air Force Academy.

What is Michael Burkes Brophy's net worth?

The estimated net worth of Michael Burkes Brophy is at least $4.51 million as of January 23rd, 2023. Mr. Brophy owns 103,023 shares of Natera stock worth more than $4,506,226 as of January 28th. This net worth approximation does not reflect any other investments that Mr. Brophy may own. Additionally, Mr. Brophy receives a salary of $661,500.00 as CFO at Natera. Learn More about Michael Burkes Brophy's net worth.

How old is Michael Burkes Brophy?

Mr. Brophy is currently 43 years old. There are 5 older executives and no younger executives at Natera. The oldest executive at Natera is Mr. Robert A. Schueren, Chief Operating Officer, who is 61 years old. Learn More on Michael Burkes Brophy's age.

What is Michael Burkes Brophy's salary?

As the CFO of Natera, Inc., Mr. Brophy earned a total compensation package of $9,757,703.00 in 2021. Mr. Brophy earned a salary of $436,732.00, stock awards of $9,096,200.00, non-equity compensation of $216,242.00, and other compensation of $8,529.00.There are 2 executives that earn more than Mr. Brophy. The highest earning executive at Natera is Mr. Steven Leonard Chapman, CEO, Pres & Director, who commands a salary of $925,590.00 per year. Learn More on Michael Burkes Brophy's salary.

How do I contact Michael Burkes Brophy?

The corporate mailing address for Mr. Brophy and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Michael Burkes Brophy's contact information.

Has Michael Burkes Brophy been buying or selling shares of Natera?

Over the course of the past ninety days, Michael Burkes Brophy has sold $238,586.08 in shares of Natera stock. Most recently, Michael Burkes Brophy sold 2,273 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a transaction totalling $94,465.88. Following the completion of the sale, the chief financial officer now directly owns 103,023 shares of the company's stock, valued at $4,281,635.88. Learn More on Michael Burkes Brophy's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 60 times. They sold a total of 96,087 shares worth more than $3,913,739.28. The most recent insider tranaction occured on January, 23rd when insider Daniel Rabinowitz sold 2,387 shares worth more than $99,203.72. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 1/23/2023.

Michael Burkes Brophy Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2023Sell2,273$41.56$94,465.88103,023View SEC Filing Icon  
1/3/2023Sell3,644$39.55$144,120.2096,814View SEC Filing Icon  
12/28/2022Sell915$39.84$36,453.6091,350View SEC Filing Icon  
12/23/2022Sell429$42.30$18,146.7089,974View SEC Filing Icon  
10/24/2022Sell2,488$42.41$105,516.0889,326View SEC Filing Icon  
9/28/2022Sell915$44.04$40,296.6085,669View SEC Filing Icon  
9/23/2022Sell433$45.30$19,614.9084,292View SEC Filing Icon  
7/22/2022Sell454$46.26$21,002.0483,648View SEC Filing Icon  
6/28/2022Sell920$39.01$35,889.2082,957View SEC Filing Icon  
6/23/2022Sell427$35.76$15,269.5281,585View SEC Filing Icon  
4/22/2022Sell458$36.14$16,552.1280,935View SEC Filing Icon  
3/28/2022Sell915$39.63$36,261.45View SEC Filing Icon  
3/23/2022Sell436$40.60$17,701.60View SEC Filing Icon  
3/10/2022Sell1,197$42.16$50,465.52View SEC Filing Icon  
1/24/2022Sell1,275$59.95$76,436.25View SEC Filing Icon  
12/28/2021Sell914$91.34$83,484.76View SEC Filing Icon  
12/23/2021Sell429$93.00$39,897.00View SEC Filing Icon  
12/10/2021Sell1,196$91.33$109,230.68View SEC Filing Icon  
12/7/2021Sell3,501$91.99$322,056.99View SEC Filing Icon  
11/10/2021Sell25,495$111.14$2,833,514.30View SEC Filing Icon  
9/27/2021Sell25,000$114.84$2,871,000.00View SEC Filing Icon  
9/23/2021Sell427$125.67$53,661.09View SEC Filing Icon  
9/10/2021Sell6,188$119.53$739,651.64View SEC Filing Icon  
6/28/2021Sell914$117.57$107,458.9898,669View SEC Filing Icon  
6/23/2021Sell430$115.18$49,527.4096,808View SEC Filing Icon  
6/10/2021Sell1,209$102.61$124,055.4996,940View SEC Filing Icon  
6/4/2021Sell3,489$97.51$340,212.3997,408View SEC Filing Icon  
5/18/2021Sell20,807$93.30$1,941,293.1099,222View SEC Filing Icon  
4/22/2021Sell3,213$110.14$353,879.8288,658View SEC Filing Icon  
4/13/2021Sell14,616$104.21$1,523,133.36106,487View SEC Filing Icon  
3/29/2021Sell4,027$83.96$338,106.9273,848View SEC Filing Icon  
3/22/2021Sell448$105.04$47,057.9264,488View SEC Filing Icon  
3/16/2021Sell2,234$110.23$246,253.8263,370View SEC Filing Icon  
3/10/2021Sell5,954$97.31$579,383.7459,058View SEC Filing Icon  
2/25/2021Sell1,899$106.73$202,680.2757,936View SEC Filing Icon  
12/24/2020Sell78,341$110.46$8,653,546.8668,169View SEC Filing Icon  
12/22/2020Sell5,208$105.48$549,339.8471,183View SEC Filing Icon  
12/10/2020Sell1,214$92.59$112,404.2659,897View SEC Filing Icon  
10/22/2020Sell1,626$68.72$111,738.7258,503View SEC Filing Icon  
9/22/2020Sell2,072$63.12$130,784.6457,347View SEC Filing Icon  
9/10/2020Sell1,236$60.77$75,111.7257,466View SEC Filing Icon  
9/4/2020Sell7,200$61.56$443,232.0061,645View SEC Filing Icon  
8/24/2020Sell1,626$65.55$106,584.3045,771View SEC Filing Icon  
7/22/2020Sell1,626$49.03$79,722.7845,771View SEC Filing Icon  
6/24/2020Sell10,021$45.77$458,661.1754,166View SEC Filing Icon  
6/22/2020Sell448$46.47$20,818.5642,139View SEC Filing Icon  
6/10/2020Sell10,273$42.38$435,369.7448,274View SEC Filing Icon  
5/22/2020Sell3,251$45.45$147,757.9526,525View SEC Filing Icon  
5/7/2020Sell833$40.00$33,320.0023,274View SEC Filing Icon  
4/6/2020Sell2,251$29.01$65,301.5124,732View SEC Filing Icon  
3/23/2020Sell1,381$24.10$33,282.1021,179View SEC Filing Icon  
3/10/2020Sell787$33.36$26,254.3220,848View SEC Filing Icon  
2/27/2020Sell200$40.00$8,000.0018,301View SEC Filing Icon  
2/3/2020Sell2,251$35.22$79,280.2219,126View SEC Filing Icon  
1/2/2020Sell625$33.86$21,162.5019,126View SEC Filing Icon  
12/23/2019Sell443$36.93$16,359.9918,944View SEC Filing Icon  
11/29/2019Sell2,859$37.50$107,212.5016,630View SEC Filing Icon  
10/30/2019Sell2,859$38.25$109,356.7516,630View SEC Filing Icon  
10/21/2019Sell15,701$40.00$628,040.0016,005View SEC Filing Icon  
9/30/2019Sell4,032$32.01$129,064.3232,878View SEC Filing Icon  
9/23/2019Sell444$33.53$14,887.3232,150View SEC Filing Icon  
9/20/2019Sell9,972$33.19$330,970.6841,005View SEC Filing Icon  
9/10/2019Sell1,206$29.50$35,577.0017,211View SEC Filing Icon  
9/4/2019Sell78$32.49$2,534.2214,268View SEC Filing Icon  
8/30/2019Sell3,484$32.97$114,867.4815,362View SEC Filing Icon  
8/8/2019Sell43,954$29.00$1,274,666.0026,690View SEC Filing Icon  
6/24/2019Sell275$25.19$6,927.2514,465View SEC Filing Icon  
6/10/2019Sell747$24.79$18,518.1314,095View SEC Filing Icon  
3/22/2019Sell273$20.20$5,514.6011,348View SEC Filing Icon  
3/11/2019Sell3,192$16.00$51,072.0013,422View SEC Filing Icon  
12/24/2018Sell449$12.39$5,563.111,788View SEC Filing Icon  
9/24/2018Sell446$23.78$10,605.881,117View SEC Filing Icon  
9/14/2018Sell108,108$24.31$2,628,105.4822,000View SEC Filing Icon  
7/2/2018Sell26,870$18.29$491,452.30View SEC Filing Icon  
6/22/2018Sell266$13.95$3,710.704,136View SEC Filing Icon  
3/26/2018Sell1,449$9.74$14,113.264,468View SEC Filing Icon  
See Full Table

Michael Burkes Brophy Buying and Selling Activity at Natera

This chart shows Michael Burkes Brophy's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Read More

Today's Range

Now: $43.74
Low: $41.89
High: $44.21

50 Day Range

MA: $39.96
Low: $35.29
High: $43.74

2 Week Range

Now: $43.74
Low: $26.10
High: $74.82


659,164 shs

Average Volume

1,300,920 shs

Market Capitalization

$4.27 billion

P/E Ratio


Dividend Yield



The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.